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The median dose of propofol administered was 70 mg 
(range: 40-120 mg), and the median dose of mid-
azolam was 2.3 mg (range: 2-4 mg). Median induction 
time of sedation was 3 min (range: 1-4 min), and me-
dian recovery time was 23 min (range: 10-40 min). A 
moderate level of sedation was achieved in 1561 (98%) 
patients, whilst a deep sedation occurred in 32 (2%) 
cases. Transient oxygen desaturation requiring further 
oxygen supplementation occurred in 8 (0.46%; 95% 
CI: 0.2%-0.8%) patients. No serious adverse event 
was observed. Cecal intubation and adenoma detec-
tion rates were 93.5% and 23.4% (27.8% for male 
and 18.5% for female, subjects), respectively.
CONCLUSION: A balanced sedation protocol provided 
a minimalization of the dose of propofol needed to tar-
get a moderate sedation for colonoscopy, resulting in 
a high safety profile for non-anesthesiologist propofol 
sedation.
© 2011 Baishideng. All rights reserved.
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Abstract
AIM: To assess the efficacy and safety of a balanced 
approach using midazolam in combination with propo-
fol, administered by non-anesthesiologists, in a large 
series of diagnostic colonoscopies.
METHODS: Consecutive patients undergoing diagnos-
tic colonoscopy were sedated with a single dose of mid-
azolam (0.05 mg/kg) and low-dose propofol (starter bo-
lus of 0.5 mg/kg and repeated boluses of 10 to 20 mg). 
Induction time and deepest level of sedation, adverse 
and serious adverse events, as well as recovery times, 
were prospectively assessed. Cecal intubation and ad-
enoma detection rates were also collected.
RESULTS: Overall, 1593 eligible patients were included. 
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INTRODUCTION
Colorectal cancer (CRC) represents a major cause of  
morbidity and mortality in western countries[1]. Despite 
the fact that it has been shown to be highly effective in 
preventing CRC incidence, colonoscopy is usually per-
ceived as an invasive and potentially painful procedure, 
resulting in a low uptake rate when compared with less 
invasive options, such as fecal tests or flexible sigmoid-
oscopy[2-4].  
To improve acceptability and tolerability of  colo-
noscopy, different protocols of  sedation have been 
adopted[5]. Such regimens have been mainly restricted to 
benzodiazepines alone or in combination with opioids, 
because of  the relatively high safety of  these substances. 
Although these drugs result in a substantial improve-
ment of  patients’ and endoscopists’s experiences, some 
drawbacks have been observed. In particular, due to 
a relatively long half-life, a slow induction of  sedation 
and a delayed discharging time with significant cost of  
monitoring have been reported[6]. Moreover, a significant 
proportion of  patients are quite dissatisfied by the sub-
optimal degree of  sedation provided by this protocol, 
and morbidity and mortality as a result of  respiratory 
depression have also been reported[7,8].
Propofol represents a short-acting sedative agonist 
of  gamma-aminobutyric acid receptor in the central 
nervous system, and it is mainly used for the induction 
and maintenance of  deep sedation during surgical proce-
dures[9]. Because of  its short half-life (2-4 min) and high 
lipid solubility, propofol has the distinct advantages of  
a rapid induction of  sedation and a fast recovery. When 
applied to gastrointestinal (GI) endoscopy, patient satis-
faction with propofol has been shown to be equivalent 
or superior to that of  benzodiazepines and/or narcot-
ics[7]. Propofol, however, is a respiratory depressant with 
a narrow therapeutic range and without a reversal agent, 
resulting in a significant risk of  inducing a too deep level 
of  sedation, complicated by hypoventilation, apnea or 
cardiovascular depression. Moreover, it lacks a reversal 
agent. For this reason, propofol is largely administered 
by anesthesiologists or anesthesiologist nurses[10]. When 
considering the very high number of  colonoscopies per-
formed worldwide - 14 million every year in the United 
States alone[11] - anesthesiologist capacity is, however, 
likely to be insufficient to assure propofol sedation for 
this procedure. 
It has been recently shown that propofol may be an 
effective and safe agent when used by non-anesthesiolo-
gists to target an adequate level of  sedation[12]. A recent 
systematic review of  the literature, including 646 080 
cases, provided adequate evidence to the American 
Gastroenterological Association for them to support 
propofol administration by non-anesthesiologists (NAP), 
because of  the extraordinary rarity of  life-threatening 
episodes[13]. Most of  these series were based on the use 
of  propofol alone, during which NAP targeted a deep 
level of  sedation. To further improve the safety profile, 
it has been suggested that a substantial reduction of  the 
propofol dose may be achieved by administering this 
drug in association with other sedative agents, such as 
midazolam or meperidine[14,15]. This protocol has been 
defined as balanced propofol sedation (BPS), and, differ-
ently from NAP, it targets a moderate level of  sedation. 
No study has addressed the use of  propofol by non-
anesthesiologists for colonoscopy in Italy, and very few 
in Europe[13]. This is largely related to the product label 
of  the drug which allows its administration only by physi-
cians trained in general anesthesia. Due to the lack of  an 
adequate anesthesiologist capacity and the low fee of  re-
imbursement for a colonoscopy in the public system, vir-
tually all the procedures are performed without propofol. 
Only a few colonoscopy series have addressed the ef-
ficacy and safety of  BPS for colonoscopy, most of  them 
including only a few hundred of  patients[14,15,17-23]. The 
purpose of  this study was to prospectively assess the 
safety and the efficacy of  endoscopist-administered BPS 
to target a moderate level of  sedation for colonoscopy 
in a large series of  consecutive patients.
MATERIALS AND METHODS 
From February 2008 to December 2009, outpatients who 
presented to our unit for diagnostic colonoscopy were 
eligible for the study if  they were between 18 and 75 years 
of  age, American Society of  Anesthesiology (ASA) 
class Ⅰ or Ⅱ, and capable of  providing written informed 
consent for study participation. Exclusion criteria were 
inability to provide informed consent, history of  allergic 
reactions or hypersensitivities to midazolam, propofol, 
eggs, or soybeans, high-risk head and neck anatomy 
(Mallampati score > 2) that could complicate airway res-
cue, sleep apnea syndrome, ASA class > Ⅱ. 
The use of  propofol by non-anesthesiologists in Italy 
is, at the time being, prevented by the specification in 
the product label that the use of  this drug is exclusively 
allowed for anesthetists or intensive care unit physicians. 
For this reason, the administration of  propofol within 
the present study has been performed under a study 
protocol that was supported by our Institution (Istituto 
Clinico Humanitas) and approved by the institutional 
review board. Nine endoscopists participated in this pro-
tocol, being authorized to administer propofol. 
Patients underwent BPS administered by an endosco-
pist who was not involved in the endoscopic procedure. 
The physicians administering sedation were certified in 
advanced cardiac life support and had also successfully 
completed an intensively structured training program in 
propofol administration and laryngeal mask use under an 
anesthesiologist tutorship. The same anesthesiologist was 
always on call during the procedure time. Baseline vital 
signs (heart rate, blood pressure, oxygen saturation) were 
obtained in all patients before induction of  sedation. 
Endoscopy-dedicated nurses also attended the procedure.
BPS was structured as follows: after a single dose 
of  midazolam (0.05 mg/kg; Hameln pharmaceuticals 
gmbh, Hameln, Germany), a starter bolus of  0.5 mg/kg 
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of  propofol (Diprivan, Astra-Zeneca, Stockholm, Swe-
den) was administered. Repeated boluses of  10 to 20 mg 
of  propofol were then administered on-demand with a 
30-60 s interval for the entire duration of  the procedure. 
Propofol bolus frequency and dose were titrated to the 
patient response, including vital signs and manifestations 
of  restlessness or discomfort. The maximum dose al-
lowed to be administered was 200 mg. Throughout the 
procedure, all patients received oxygen 2 L/min by nasal 
cannula. Continuous pulse oximetry, heart rate, electro-
cardiography, and end-expiratory carbon dioxide were 
monitored, with blood pressure being assessed at 5-min 
intervals. Level of  sedation was evaluated according to 
the Scale for assessing Alertness/Sedation (MOAA/S), 
as reported in Table 1. In detail, deep sedation was de-
fined as MOAA/S 1, moderate as MOAA/S 2-4, and 
minimal as MOAA/S 5. The following parameters were 
recorded: patient demographics, procedure indication 
and duration, midazolam dose, propofol dose, induc-
tion time, recovery time, cecal intubation rate, and polyp 
detection rate. The baseline values and changes in vital 
signs or oxygen saturation (SpO2) from the baseline were 
also recorded. Adverse events were defined as hypoxia 
(i.e., a reduction in oxygen saturation < 90% for more 
than 20 s) requiring supplemental oxygen (O2) by nasal 
cannula (NC) in excess of  2 L/min; and transient hypo-
tension (< 90 mmHg) or bradycardia (< 60 beats/min) 
not requiring any active medical treatment. Serious ad-
verse events were defined as hypoxia requiring positive 
pressure ventilation or laryngeal mask use; hypotension 
(< 90 mmHg) or bradycardia (< 60 beats/min) requir-
ing medical treatment (i.e., infusion of  liquid) other than 
propofol titration; and any event requiring the adminis-
tration of  a benzodiazepine antagonist (flumazenil). Af-
ter the procedure, the patients were transported to the re-
covery room where blood pressure, SpO2 and heart rate 
were measured continuously until discharge. Discharge 
was possible when blood pressure was within 20% of  
the initial value, SpO2 > 90%, and the patient was able to 
drink and walk autonomously. Recovery time was mea-
sured from the time the patient entered the recovery area 
until departure by the recovery room nurse. 
RESULTS 
During the study period, 1593 eligible patients were in-
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 Responsiveness Score
 Responds readily to name spoken in normal tone 5
 Lethargic response to name spoken in normal tone 4
 Responds only after name is called loudly and/or repeatedly 3
 Responds only after mild prodding or shaking 2
 Responds only after painful trapezius squeeze 1
 Does not respond to painful trapezius squeeze 0
Table 1  Scale for assessing Alertness/Sedation cluded. Of  these, 789 (49%) were male, the median age 
being 60 years (range: 22-75 years). Clinical indication 
for colonoscopy was evaluation of  symptoms in 876 
(55%) cases, screening or surveillance of  a previous neo-
plastic lesion in 542 (34%), work-up of  a positive fecal 
test in 96 (6%), and follow up of  inflammatory bowel 
diseases in the remaining 79 (5%) cases.
Baseline mean heart rate and mean blood pressure 
were 71 ± 13 beats per min and 103 ± 16 mmHg, respec-
tively. BPS was administered to all the patients. The me-
dian dose of  midazolam was 2.3 mg (range: 2-4 mg), and 
the median dose of  propofol administered was 70 mg 
(range: 40-120 mg). The median induction time of  seda-
tion (i.e., between the initiation of  sedation and colono-
scope insertion) was 3 min (range: 1-4 min). The deepest 
level of  sedation was moderate in 1561 (98%) patients 
and deep in the remaining 32 (2%) cases. General anes-
thesia was not observed in any patient.
There was no serious adverse event related to any of  
the 1593 patients. The only adverse events observed with 
BPS were episodes of  transient oxygen desaturation re-
quiring O2 supplementation by NC in excess of  2 L/min 
in 8 (0.46%; 95% CI: 0.2%-0.8%) patients. No patient 
required mask ventilation or endotracheal intubation. 
Although a transient decrease in blood pressure was 
common (446 patients, 28%), no episodes of  sustained 
hypotension or bradycardia requiring active therapy were 
observed. No patient required administration of  a benzo-
diazepine antagonist. Median recovery time was 23 min 
(range: 10-40 min). 
The overall cecal intubation rate was 93.5%, corre-
sponding to 1491 complete colonoscopies. Incomplete 
procedures were due to poor bowel cleaning in 72 (4.5%) 
patients and sigmoid strictures in 30 (2%) cases. The 
median procedural time was 11.3 min (range: 9-22 min), 
consisting of  a median intubation time of  4 min (range: 
3-9 min) and a median withdrawal time of  6.3 min (range: 
4.2-11.9 min). Adenoma detection rate was 23.4% (27.8% 
for male, and 18.5% for female subjects). No major 
procedure-related complication occurred.
DISCUSSION 
Our study showed that a BSP protocol, based on the co-
administration of  propofol with benzodiazepine, was a 
feasible, effective and safe approach for colonoscopy in 
a large series of  consecutive patients. In particular, fol-
lowing a careful and rigid selection of  the patients, BSP 
was successfully administered by non-anesthesiologist 
endoscopists without requiring anesthesiologist interven-
tion in any of  the cases. No BSP-related serious adverse 
event occurred in the study population, as outlined by 
the evidence that a midazolam-reversal agent was not 
needed in any patient. A transient oxygen desaturation 
was observed in only 0.5% of  the study population, and 
it was treated conservatively in all cases.
The high safety profile of  the BSP observed in our 
study appears to be strictly related to the very low dose 
Repici A et al . Balanced propofol sedation for colonoscopy
of  propofol needed to target a moderate sedation, be-
cause of  the additional effect of  midazolam. Despite 
the fact that this was a non-randomized study in which a 
propofol-alone arm was not included, the median dose 
of  propofol shown in the present study, corresponding 
to 70 mg per patient, appeared to be much lower than 
the 200-400 mg range described in previous propofol-
alone series[16]. A similarly low propofol dose was also 
reported in previous series in which BSP was adopt-
ed[14,15,17-23]. When considering the potential legal implica-
tions related to NAP, the ability to minimize the dose 
of  propofol needed appears as an attractive goal for the 
endoscopists. The very low rate of  oxygen desaturation 
observed in our study may also be related to the system-
atic adoption of  capnography to monitor our patients. It 
has been suggested that capnography may anticipate the 
diagnosis of  propofol-induced hypoventilation as com-
pared to the simple assessment of  oxygen saturation[24].
It could be argued, however, that co-administration 
of  midazolam could reduce the propofol-related advan-
tages. In particular, the slow metabolization of  benzodi-
azepines could result in a prolonged recovery time, re-
ducing the efficiency of  an endoscopic turnover system. 
The median recovery time in our series was consistently 
lower than 30 min. This value favorably compares with 
previous accounts of  midazolam alone, in which a recov-
ery time as long as 70 min was reported[25]. Such a differ-
ence in favor of  the BSP regimen is presumably due to 
the relatively low dose of  midazolam administered, the 
median being 2.1 mg per patient. Moreover, midazolam 
was administered only at the beginning of  the procedure 
as a bolus, so that the drug started to be metabolized 
during the procedure itself, lasting on average 11 min.
Quality of  colonoscopy procedures in our series 
appeared to reach the required standards, showing no 
interference of  BSP in the diagnostic or operative proce-
dures. In particular, the adjusted cecal intubation rate of  
93.5% in a mixed setting with symptomatic and screen-
ing indications is remarkably superior to the 80.7% 
recently reported in an Italian survey, in which the use 
of  propofol was not reported[26]. Of  note, in a similarly 
designed Italian study, it was observed that the intuba-
tion rate in sedation-assisted colonoscopies was superior 
to that of  those performed without sedation[27]. 
It could be argued that the results of  our study were 
not unexpected; the safety of  BSP having already been 
shown in previous studies. However, most of  these 
series included only 100-200 patients[14,15,17-23], so that a 
greater confirmation of  BSP safety in over 1500 subjects 
was needed. Moreover, this is the first Italian study in 
which NAP was applied to colonoscopy, and, more gen-
erally, to adults. This would appear to be of  major im-
portance when considering that the use of  propofol in 
Italy is prevented by an unequivocal recommendation in 
the product label stating that only anesthesiologists are 
allowed to administer such a drug. The safety profile of  
BSP in our study should call for dedicated studies aiming 
to ascertain whether such a recommendation is really a 
protection for the patients and whether it is consistent 
with literature data or simply represents an obstacle pre-
venting a safe propofol-assisted colonoscopy to most pa-
tients. Indeed, in Italy, due to the lack of  anesthesiologist 
capacity, virtually all the colonoscopies are performed 
without propofol, using at best benzodiazepines and/or 
narcotics[25].
 There are limitations to the present analysis. Our 
main target was to evaluate BSP efficacy in targeting a 
moderate level of  sedation when administered by non-
anesthesiologists, whilst we did not assess the level of  
satisfaction of  patients or endoscopists with our sedation 
protocol. However, there is enough evidence regarding 
a higher satisfaction level with propofol as compared to 
midazolam[16]. Moreover, the short induction time clearly 
reflects a propofol type of  sedation rather than the ef-
fect of  midazolam. Secondly, we did not compare the 
propofol/midazolam BSP with other protocols, such as 
propofol alone or propofol with narcotics with or with-
out midazolam. However, most of  the propofol-related 
toxicity is associated with its narrow therapeutic window, 
so that it is unlikely that such a high safety profile would 
be achieved by protocols based on doses of  propofol 
substantially larger than those reached in our experience. 
Thirdly, we did not blind the discharging nurse regarding 
the type of  sedation, so that we cannot exclude a bias in 
the computation of  the recovery time. Fourthly, we did 
not assess the alertness level after several hours from 
discharge, so that we cannot exclude a prolonged effect 
of  midazolam bolus in our series. Fifthly, although our 
study included over 1500 subjects, we cannot exclude 
extremely rare events that have been associated with 
the use of  propofol, such as neurologic injuries or even 
death. However, the lack of  severe episodes of  respira-
tory or cardiovascular depression reassures us about the 
safety of  BSP. Moreover, no death has been reported 
up to now with the use of  NAP in colonoscopy; all the 
cases having been associated with upper GI endoscopy 
or biliary maneuvers[13]. According to the study protocol, 
we systematically used a non-anaesthesiologist physician 
for monitoring propofol administration. It could be ar-
gued that this represents a waste of  resources, requiring 
two endoscopists to perform one procedure. However, 
this simply reflects a prudent choice within the study 
protocol to prevent eventual litigation for an off-label 
use of  the drug. It has already been shown that ap-
propriately trained nurses may assist the endoscopist in 
propofol administration and sedation monitoring with a 
clear saving of  resources. Finally, we did not use specific 
scales of  recovery after the completion of  the colonos-
copy, considering discharge possible on the basis of  
blood pressure, SpO2, and the patients’ ability to drink 
and walk autonomously.
In conclusion, we report a large consecutive series 
showing the efficacy and safety of  BSP for colonoscopy, 
when administered by non-anesthesiologists. When 
considering the controversy regarding NAP use for GI 
endoscopy, the very low dose of  propofol allowed by the 
co-administration of  midazolam appears to be a rational 
approach to maximize sedation efficacy and to minimize 
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propofol toxicity at the same time.
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Non-anesthesiologists propofol administration (NAP) represents an effective 
and safe alternative to sedation with benzodiazepines/narcotics for colonos-
copy. NAP generally involves the administration of propofol alone to target a 
deep level of sedation. By associating propofol with other sedative agents, such 
as midazolam, a moderate level of sedation may be targeted, resulting in a 
substantial reduction of the propofol dose. 
Research frontiers
Despite being validated in small controlled trials, such a balanced propofol se-
dation has never been tested in a large cohort.
Innovations and breakthroughs
In a large prospective study involving 1593 patients, a balanced propofol seda-
tion consisting of the co-administration of propofol and midazolam resulted in 
a moderate level of sedation in 98% of colonoscopies. Recovery time also ap-
peared to be favorably short. Such a balanced protocol of sedation appeared 
to be highly safe, the only serious event being a transient oxygen desaturation 
requiring further oxygen supplementation in less than 1% of the patients. The 
median dose of propofol administered was 70 mg, being less than 120 mg in 
the entire series. The overall cecal intubation and adenoma detection rates 
were 93.5% and 23.4%, respectively. No major procedure-related complication 
occurred.
Applications
A balanced administration of propofol by non-anesthesiologists may be safely 
implemented in dedicated centers.
Peer review
The paper assessed the efficacy and safety of a balanced approach using mid-
azolam in combination with propofol administered by non-anesthesiologists in a 
large series of diagnostic colonoscopies. It is very interesting.
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